Cyclazodone

Chemical compound
  • none
Legal statusLegal status
  • In general: legal
Identifiers
  • (RS)-2-(cyclopropylamino)-5-phenyl-1,3-oxazol-4-one
CAS Number
  • 14461-91-7 checkY
PubChem CID
  • 26701
ChemSpider
  • 24875 ☒N
UNII
  • O8U55ZRL9K
ChEMBL
  • ChEMBL2106536 ☒N
Chemical and physical dataFormulaC12H12N2O2Molar mass216.240 g·mol−13D model (JSmol)
  • Interactive image
ChiralityRacemic mixture
  • C1CC1NC2=NC(=O)C(O2)C3=CC=CC=C3
InChI
  • InChI=1S/C12H12N2O2/c15-11-10(8-4-2-1-3-5-8)16-12(14-11)13-9-6-7-9/h1-5,9-10H,6-7H2,(H,13,14,15) ☒N
  • Key:DNRKTAYPGADPGW-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Cyclazodone is a centrally acting stimulant drug developed by American Cyanamid Company in the 1960s.[1] The drug is related to other drugs such as pemoline and thozalinone. It displayed a favorable therapeutic index and margin of safety in comparison to Pemoline and other N-lower-alkyl-substituted Pemoline derivatives.[2] The patents concluded that Cyclazodone possessed properties efficacious in reducing fatigue and as a potential anorectic.[3] Structural congeners of Pemoline have been described as "excitants with unique properties distinguishing them from the sympathomimetic amines" whilst displaying less stimulatory activity and toxicity compared to amphetamine.[4]

It is included under the World Anti-Doping Agency prohibited list.[5]

Safety

Cyclazodone has not been evaluated by the United States Food and Drug Administration for use in humans as a nootropic, anorectic, or stimulant and thus safety information on Cyclazodone is lacking. However, in studies relating to the therapeutic uses of Cyclazodone, it was noted that Cyclazodone exhibited less cardiotoxic and hepatotoxic effects than D-Amphetamine in studies on mice.[2]

See also

References

  1. ^ US 3321470, Howell Jr CF, Hardy RA, Quinones N, "5-Arylidene-2-Amino-2-Oxazolin-4-Ones", issued 23 May 1967, assigned to American Cyanamid 
  2. ^ a b US 3609159, De Marne V, Pierre D, Guidicelli RL, Najer H, "5-Phenyl-2-Cyclopropylamino-4-Oxazolinone", issued 28 September 1971, assigned to Les Laboratoires Dausse 
  3. ^ GB 1005738, De Marne V, Pierre D, Guidicelli RL, Najer H, "5-Phenyl-2-Cyclopropylamino-4-Oxazolinone", issued 29 September 1965, assigned to Les Laboratoires Dausse 
  4. ^ Greenblatt EN, Osterberg AC (July 1965). "Some pharmacologic properties of thozalinone, a new excitant". Toxicology and Applied Pharmacology. 7 (4): 566–78. doi:10.1016/0041-008x(65)90042-6. PMID 4378772.
  5. ^ "World Anti-Doping Agency 2008 Prohibited List" (PDF). World Anti-Doping Agency. 22 September 2007.
  • v
  • t
  • e
AdamantanesAdenosine antagonistsAlkylaminesAmpakinesArylcyclohexylaminesBenzazepinesCathinonesCholinergicsConvulsantsEugeroicsOxazolinesPhenethylamines
PhenylmorpholinesPiperazinesPiperidinesPyrrolidinesRacetamsTropanesTryptaminesOthers
  • v
  • t
  • e
DRAsTooltip Dopamine releasing agents
NRAsTooltip Norepinephrine releasing agents
SRAsTooltip Serotonin releasing agents
Others
See also: Receptor/signaling modulators • Monoamine reuptake inhibitors • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e